Work

Abstract CT071: Phase I trial of trastuzumab deruxtecan in combination with neratinib in solid tumors with HER2 alterations (NCI 10495)

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct071

Authors: Andrew A. Davis, Haeseong Park, Ecaterina E. Dumbrava, Nataliya V. Uboha, Aparna Kalyan, Farshid Dayyani, Mili Arora, Miguel A. Villalona-Calero, Haider S. Mahdi, Reema A. Patel, Floor Backes, Jessica Porzel, Whitney L. Hensing, Cheryl Pickett, Cynthia X. Ma, Ron Bose

Institutions: Washington University in St. Louis, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, University of Wisconsin System, University of Wisconsin–Madison, Northwestern University, University of California, Irvine, University of California, Davis, City of Hope, University of Pittsburgh, University of Pittsburgh Medical Center, University of Kentucky, The Ohio State University, Saint Luke's Hospital, National Cancer Institute

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409822142

Cites:

Cited by: 3

Related to: 10